Structure of Renal Disease: A Systematic Framework for Clinical Organization
Learning Objectives
By the end of this handout, you will: - Understand the systematic organization of renal disease by anatomic location - Apply a structured approach to differential diagnosis of kidney disease - Recognize how pathophysiologic mechanisms determine clinical presentation - Use this framework to organize clinical thinking during case discussions - Integrate assessment of both structure (anatomy) and function (physiology)
Introduction: Why Organization Matters
Nephrology can seem overwhelming with hundreds of disease entities. This handout provides a structured framework that organizes all renal disease by: 1. Anatomic location — Where in the kidney is the disease? 2. Pathophysiologic mechanism — What is the disease doing? 3. Clinical presentation — How does the patient present? 4. Diagnostic approach — How do we confirm the diagnosis?
This systematic approach transforms memorization into logical clinical reasoning.
PART 1: STRUCTURAL ANATOMY AND ASSESSMENT
I. GROSS (MACROSCOPIC) KIDNEY ANATOMY
Definition: Large-scale kidney architecture visible on imaging (ultrasound, CT, MRI)
A. Size Assessment
- Normal: 11-12 cm length; 120-170 g weight per kidney
- Enlarged kidneys:
- Polycystic kidney disease (ADPKD, ARPKD)
- Early diabetic nephropathy
- Lymphoma, leukemia
- Amyloidosis
- Shrunken kidneys:
- Chronic kidney disease (end-stage fibrosis)
- Chronic glomerulonephritis
- Chronic pyelonephritis
- Renal infarction (old)
B. Cystic Lesions
- Single cysts: Benign; common in older adults
- Multiple cysts:
- Autosomal dominant polycystic kidney disease (ADPKD) → progressive to ESRD
- Autosomal recessive polycystic kidney disease (ARPKD) → neonatal presentation
- Simple cysts (benign variant)
- Cystic complications: Infection, hemorrhage, rupture → pain, hematuria
C. Masses
- Solid tumors:
- Renal cell carcinoma (most common)
- Oncocytoma, angiomyolipoma (benign variants)
- Lymphoma (can be primary or secondary)
- Assessment: Size >3 cm concerning; vascular invasion indicates aggressive disease
D. Drainage Assessment
- Hydronephrosis: Dilation of renal pelvis/calyces from obstruction
- Causes: Stones, strictures, malignancy, fibrosis
- Risk: Progressive kidney damage if unrelieved
- Atrophic kidneys with normal drainage: Chronic disease (fibrosis, atrophy)
E. Assessment Methods
- Ultrasound: First-line (no radiation); assesses size, echogenicity, hydronephrosis, doppler flow
- CT (non-contrast): Gold standard for stones; excellent for masses
- MRI: Best for patients avoiding radiation; limited use in severe CKD (gadolinium risk)
- Doppler ultrasound: Assesses renal artery flow; screens for renal artery stenosis
II. MICROANATOMY (HISTOLOGIC STRUCTURE)
Definition: Tissue-level kidney architecture requiring kidney biopsy
A. The Nephron and Glomerular Changes
Normal Structure: - Glomerulus: Fenestrated endothelium + basement membrane + podocytes - Capillaries: 50 m² filtration surface area - Mesangium: Structural support, immune clearance
Pathologic Changes Seen on Biopsy: - Proliferative lesions: Cell multiplication (mesangial, endothelial) - Examples: IgA nephropathy, MPGN, post-infectious GN - Significance: Active inflammation; often responsive to treatment
- Membranous changes: Basement membrane thickening
- Examples: Membranous nephropathy, diabetic disease
- Significance: Structural damage; may indicate chronic process
- Sclerosis: Fibrosis/scarring of glomeruli
- Examples: FSGS, late diabetic disease, chronic hypertension
- Significance: Irreversible damage; worse prognosis
- Crescent formation: Extracapillary proliferation (ominous sign)
- Examples: RPGN, ANCA vasculitis, anti-GBM disease
- Significance: Rapidly progressive; requires urgent treatment
B. Tubular Changes
- Acute tubular injury: Cell swelling, necrosis (acute tubular necrosis)
- Chronic changes: Atrophy, fibrosis (tubular atrophy and interstitial fibrosis—TAIF)
- Cast formation: Proteinous or cellular casts within tubules
C. Interstitial Changes
- Interstitial inflammation: Acute interstitial nephritis (AIN)
- Interstitial fibrosis: Progressive scarring (TAIF—most common final pathway of all CKD)
- Immune infiltrates: Cell type indicates cause (eosinophils in drug AIN, lymphocytes in infection)
D. Vascular Changes
- Intimal fibrosis: Narrowed arterioles (hypertensive/diabetic injury)
- Arterial stenosis: Renal artery narrowing (atherosclerotic or fibromuscular dysplasia)
- Thrombosis: Vessel occlusion (thrombotic microangiopathy)
PART 2: PHYSIOLOGIC FUNCTION AND DYSFUNCTION
I. GLOMERULAR FILTRATION (GFR = Kidney’s Primary Job)
Normal Function: - GFR ~100-120 mL/min/1.73m² (young adult) - Filters 180 L/day while retaining proteins and cells - Determined by: Hydrostatic pressure, oncotic pressure, filtration coefficient
Mechanisms of GFR Reduction:
| Mechanism | Pathophysiology | Examples |
|---|---|---|
| Decreased filtration pressure | Low perfusion pressure | Hypovolemia, cardiorenal syndrome, renal artery stenosis |
| Increased downstream pressure | Obstruction of tubular flow | Stones, strictures, malignancy |
| Loss of filtration barrier | Structural damage to glomerulus | Glomerulonephritis, diabetic disease |
| Loss of nephrons | Permanent nephron loss | End-stage disease, surgical loss |
II. TUBULAR FUNCTION DISORDERS
Tubular Reabsorption Defects:
A. Sodium Handling
- Normal: Proximal tubule reabsorbs 65% of filtered Na+
- Pathology: Loop diuretics block ascending limb; thiazides block DCT
- Clinical result: Salt wasting or salt retention depending on location/medication
B. Water Balance
- Normal: ADH allows water reabsorption in collecting duct
- Pathology:
- Central diabetes insipidus: Inadequate ADH production
- Nephrogenic diabetes insipidus: Kidney unresponsive to ADH
- SIADH: Excess ADH → water retention
- Clinical result: Polyuria (DI) or hyponatremia (SIADH)
C. Electrolyte Handling (K+, Mg2+, Ca2+, PO4³⁻)
- Potassium: DCT and collecting duct excrete; aldosterone increases excretion
- Magnesium: Thick ascending limb reabsorbs; PPI use causes wasting
- Calcium: PTH increases DCT reabsorption; varies inversely with sodium
- Phosphate: Normally filtered; PTH decreases proximal reabsorption
- Clinical result: Hyperkalemia in ESRD, hypomagnesemia from PPIs, secondary hyperparathyroidism in CKD
D. Acid-Base Regulation
- Proximal tubule: Reabsorbs filtered HCO₃⁻ (99% normally)
- Distal tubule/collecting duct: Secretes H+ via intercalated cells
- Pathology: Renal tubular acidosis (RTA) from impaired H+ or HCO₃⁻ handling
- Clinical result: Non-anion-gap metabolic acidosis despite normal anion gap
E. Protein/Albumin Reabsorption
- Normal: Proximal tubule reabsorbs virtually all filtered proteins (<150 mg/day urine)
- Pathology: Proteinuria occurs when filtered protein exceeds reabsorptive capacity
- Significance: Proteinuria is both sign of kidney damage AND risk factor for progression
F. Glucose Handling
- Normal: All filtered glucose reabsorbed; urine glucose = 0
- Pathology: Glucosuria indicates either hyperglycemia or proximal dysfunction
- Clinical result: Diabetes mellitus or Fanconi syndrome
G. Organic Acid Handling
- Normal: Uric acid secreted in proximal tubule
- Pathology: Impaired secretion → hyperuricemia; increased reabsorption possible
- Clinical result: Gout risk increases in CKD; hyperuricemia promotes stone formation
III. ENDOCRINE FUNCTIONS
A. Blood Pressure Regulation
- Mechanism: RAAS activation by decreased renal perfusion
- Pathophysiology: Renin → Angiotensin II → Vasoconstriction & aldosterone → sodium retention
- Failure in CKD: Inability to control extracellular volume → hypertension
B. Erythropoietin Production
- Normal: Peritubular fibroblasts produce EPO in response to hypoxia
- Pathophysiology: EPO deficiency in CKD → anemia (normocytic, hypoproliferative)
- Clinical result: Hematocrit drops ~10 points in ESRD without treatment
C. Vitamin D Synthesis
- Normal: Proximal tubule converts 25-OH vitamin D → active 1,25-dihydroxy vitamin D
- Pathophysiology: Impaired conversion in CKD despite normal 25-OH levels
- Clinical result: Secondary hyperparathyroidism from low calcitriol
D. Metabolic Functions
- Gluconeogenesis: During fasting; impaired in CKD
- Ammonia production: Critical for acid excretion; reduced in CKD
- Drug metabolism: Renally cleared drugs accumulate in CKD
PART 3: PATHOPHYSIOLOGY — DISEASE MECHANISMS
I. CHRONIC KIDNEY DISEASE (CKD)
Definition: Progressive, irreversible loss of kidney function staged by eGFR
Two Main Categories:
A. Glomerular Diseases
Mechanism: Primary immune-mediated damage to glomerulus - Examples: - IgA nephropathy (hematuria, progressive) - Membranous nephropathy (nephrotic proteinuria) - FSGS (progressive proteinuria) - Lupus nephritis (systemic disease) - ANCA vasculitis (rapidly progressive)
Presentation: Often presents with proteinuria ± hematuria
B. Interstitial/Tubular Disease
Mechanism: Primary damage to tubules and interstitium, glomeruli secondary - Examples: - Diabetic nephropathy (progressive, but mixed glomero-tubular) - Hypertensive nephrosclerosis (chronic hypertension damage) - Chronic pyelonephritis (recurrent infections) - Drug-induced CKD (NSAIDs, lithium, amphotericin) - Reflux nephropathy (vesicoureteral reflux)
Presentation: May present without proteinuria initially; later develops as glomerulosclerosis occurs
C. Final Common Pathway: TAIF
TAIF = Tubular Atrophy and Interstitial Fibrosis - Significance: ALL chronic diseases progress to TAIF if untreated - Mechanism: Fibroblast proliferation, myofibroblast transformation, collagen deposition - Implication: Irreversible once established; can’t regain function once TAIF prominent
II. ACUTE KIDNEY INJURY (AKI)
Definition: Acute loss of kidney function, potentially reversible
Three Main Categories:
A. Prerenal AKI (55-60% of cases)
Mechanism: Decreased renal perfusion without direct kidney damage - Causes: - Hypovolemia: Hemorrhage, dehydration, GI losses, burns - Decreased effective circulating volume: CHF, cirrhosis, nephrotic syndrome - Systemic vasodilation: Sepsis, medications - Renal vasoconstriction: ACEi/ARB in specific patients, NSAIDs - Aortic dissection, renal artery stenosis
Key Finding: FENa <1% (kidney conserves sodium appropriately)
Prognosis: Reversible with treatment of underlying cause; responds to fluid resuscitation
B. Intrinsic (Parenchymal) AKI (35-40% of cases)
B1. Acute Tubular Necrosis (ATN) - Mechanism: Direct injury to tubular epithelium - Causes: - Ischemic: Prolonged renal hypoperfusion (shock, severe dehydration) - Nephrotoxic: Medications (aminoglycosides, amphotericin B, cisplatin), contrast dye, myoglobin (rhabdo), hemoglobin (massive hemolysis), uric acid (tumor lysis) - Key Finding: FENa >2%, muddy brown granular casts - Prognosis: Reversible with appropriate supportive care; typically recovers in 1-3 weeks
B2. Acute Interstitial Nephritis (AIN) - Mechanism: Immune-mediated inflammation of interstitium and tubules - Causes: Medications (NSAIDs, antibiotics—especially beta-lactams, PPIs), infections, autoimmune - Key Finding: Eosinophiluria, pyuria without bacteria - Prognosis: Often reversible if offending agent removed promptly; permanent damage if delayed
B3. Acute Glomerulonephritis - Mechanism: Immune complex deposition or vasculitis affecting glomeruli - Causes: Post-infectious GN, ANCA vasculitis, anti-GBM disease, lupus, IgA nephropathy (acute exacerbation) - Key Finding: RBC casts, dysmorphic RBCs, hematuria + proteinuria - Prognosis: Varies by type; RPGN requires urgent plasma exchange; others may recover with immunosuppression
B4. Other Intrinsic Causes - Vascular: Renal infarction, thrombosis, dissection, thrombotic microangiopathy (HUS, TTP, scleroderma)
Key Finding: Elevated LDH, low platelets, schistocytes on smear in microangiopathy
C. Postrenal AKI (5% of cases)
Mechanism: Urinary obstruction preventing urine flow - Causes: - Upper urinary tract: Stones, strictures, malignancy, fibrosis - Lower urinary tract: BPH, urethral stricture, functional (severe constipation) - Key Finding: Hydronephrosis on ultrasound - Prognosis: Excellent if decompressed promptly; permanent damage if prolonged obstruction
Clinical Pearl: Always ask “Did the AKI develop suddenly in previously well kidneys (AKI) or is there a history of progressive kidney disease (CKD)?” Baseline creatinine is essential for interpretation.
III. HYPERTENSION IN KIDNEY DISEASE
Two-Way Relationship: 1. Hypertension causes kidney disease → chronic hypertensive injury → nephrosclerosis 2. Kidney disease causes hypertension → inability to excrete sodium → volume expansion and RAAS activation
Mechanisms: - Renin-angiotensin-aldosterone system: Renal hypoperfusion → renin release → vasoconstriction and sodium retention - Volume expansion: Impaired sodium excretion in CKD → fluid retention → hypertension - Endothelial dysfunction: Vascular injury from proteinuria and hemodynamic changes
Clinical Implications: - Tight BP control slows CKD progression - ACEi/ARB first-line (reduce intraglomerular pressure, reduce proteinuria) - Salt restriction critical for volume-dependent hypertension
PART 4: CLINICAL INTEGRATION — USING THE FRAMEWORK
How to Organize Your Thinking About Any Renal Disease
Step 1: Assess STRUCTURE (What does it look like?) - Is the kidney enlarged, normal, or shrunken? - Are there cysts, masses, or obstruction? - Biopsy findings? (If available)
Step 2: Assess PHYSIOLOGY (What is broken?) - Is GFR decreased? (By how much? How fast?) - Is there proteinuria? (Glomerular disease likely) - Are there electrolyte abnormalities? (Tubular dysfunction likely) - Is there acid-base disturbance? (Tubular secretion problem likely)
Step 3: Determine PATHOPHYSIOLOGY (Why is it broken?) - Is this a glomerular disease? (RBC casts, proteinuria, hematuria) - Is this tubular/interstitial disease? (Electrolyte wasting, minimal proteinuria initially) - Is this acute or chronic? (Rapidly rising Cr = acute; slow decline = chronic) - Is this reversible (AKI) or permanent (CKD)?
Step 4: Apply CLINICAL KNOWLEDGE (What do we do about it?) - What is the cause? (Needs specific treatment) - Is it progressive? (Needs prevention of progression) - Are there complications? (Hypertension, proteinuria, anemia, bone disease)
Example Case Integration
Case: 65-year-old with 10-year history of hypertension, now eGFR 35 mL/min, creatinine 2.0 (baseline 1.0 three years ago).
Structure: Kidney ultrasound shows normal-sized kidneys with normal echogenicity, no hydronephrosis Physiology: eGFR 35 (Stage 3b CKD); spot protein/creatinine 2.5 g/g (heavy proteinuria) Pathophysiology: Chronic disease (slow creatinine rise over 3 years); glomerular disease component (heavy proteinuria) overlaying hypertensive/diabetic injury Clinical: Likely hypertensive nephrosclerosis with diabetic overlap (if diabetic), or primary glomerular disease. Needs: tight BP control, ACEi/ARB, low sodium diet, monitoring for complications.
Quick Reference Tables
Anatomic Patterns in Kidney Disease
| Location | Disease Type | Example | Presentation |
|---|---|---|---|
| Glomerulus | Glomerulonephritis | IgA nephropathy, FSGS, membranous | Hematuria, proteinuria, RBC casts |
| Tubule | Tubular dysfunction | Renal tubular acidosis, Bartter syndrome | Electrolyte abnormalities, minimal proteinuria |
| Interstitium | Interstitial nephritis | Drug-induced AIN, chronic pyelonephritis | Pyuria, eosinophiluria, sometimes fever/rash |
| Vasculature | Vascular disease | Renal artery stenosis, renal infarction | Hypertension, AKI, flank pain |
| Collecting System | Obstruction | Kidney stone, malignancy | Hydronephrosis, obstruction on imaging |
Progression Patterns
| Pattern | Reversibility | Examples | Prognosis |
|---|---|---|---|
| Acute (days-weeks) | Reversible if treated | ATN, AIN, prerenal | Can return to baseline |
| Progressive chronic (months-years) | Partially reversible | Early CKD, nephrotic syndrome | Slowing possible with treatment |
| End-stage (years) | Irreversible | ESRD with TAIF | Requires RRT |
Summary: The “Big Picture” Framework
All kidney disease fits into this structure:
- Where: Glomerulus, tubule, interstitium, vessels, or collecting system?
- How bad: Normal → CKD 1 → CKD 2 → CKD 3a → CKD 3b → CKD 4 → CKD 5/ESRD?
- How fast: Acute (reversible) or chronic (progressive)?
- Why: Specific diagnosis determines specific treatment
- What next: Prevent progression, manage complications, prepare for RRT if needed
Clinical Pearl Summary
- All CKD ultimately progresses to TAIF (tubular atrophy and interstitial fibrosis) — the final common pathway
- Proteinuria is both a marker and driver of progression — reduce it aggressively
- Tight BP control is universal therapy — all CKD patients benefit
- Early intervention is key — once ESRD develops, only RRT or transplant available
- Know the baseline creatinine — it’s the most important number you’re missing
Practice Integration Questions
Distinguish: Glomerular disease typically presents with _____ and _____; tubular disease may have _____ but preserve _____.
Classify: A patient with hypertension, hypokalemia, metabolic alkalosis, and elevated renin likely has _____ dysfunction at the _____ level.
Predict: Progressive CKD with rising proteinuria will eventually develop complications: _____, _____, _____, and _____.